Breaking News Instant updates and real-time market news.

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

, AIMT

Aimmune

$24.66

(0.00%)

17:57
09/13/19
09/13
17:57
09/13/19
17:57

DBV Technologies falls 2% after FDA panel votes in favor of Aimmune drug

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

AIMT

Aimmune

$24.66

(0.00%)

  • 13

    Sep

DBVT DBV Technologies
$10.22

0.595 (6.18%)

06/17/19
06/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DBV Technologies (DBVT) initiated with a Buy at Goldman Sachs. 2. Amicus (FOLD) initiated with a Buy at H.C. Wainwright. 3. Viper Energy (VNOM) initiated with a Buy at SunTrust. 4. GNC Holdings (GNC) initiated with a Hold at Jefferies. 5. Eventbrite (EB) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/19
WEDB
07/12/19
NO CHANGE
Target $79
WEDB
Outperform
Aimmune selloff on ICER report overdone, says Wedbush
Wedbush analyst Liana Moussatos views the selloff yesterday in shares of Aimmune Therapeutics as overdone. The Institute for Clinical and Economic Review on Wednesday released a final report on emerging desensitization treatments for peanut allergy and compared the clinical effectiveness and value of Aimmune's AR101, DBV Technologies' (DBVT) Viaskin and non-commercialized oral immunotherapy for treatment of peanut allergy, Moussatos tells investors in a research note. However, the ICER report excluded long-term desensitization and patient quality-of-life results for AR101 and hence failed to recognize the full value of AR101 immunotherapy for peanut allergy, says the analyst. She sees an "excellent entry point" into Aimmune shares following yesterday's selloff and reiterates an Outperform rating on the name wih a $79 price target.
08/05/19
HCWC
08/05/19
NO CHANGE
Target $25
HCWC
Buy
H.C. Wainwright reiterates Buy on DBV ahead of expected BLA resubmission
H.C. Wainwright analyst Andrew Fein says that as DBV Technologie (DBVT) moves forward towards an anticipated Biologics License Application resubmission for Viaskin Peanut in Q3, he continues to be supportive of the overall value, safety, and efficacy of the Viaskin Peanut program. Following organizational updates, a "straightforward BLA resubmission could refresh investors' confidence in management, while addressing the regulatory overhang," Fein tells investors in a research note. He reiterates a Buy rating on DBV shares with a $25 price target. His confidence in the Viaskin Peanut program has been based on "exceptional safety and sufficient efficacy to manage the risk of accidental exposure." The analyst believes these properties differentiate Viaskin Peanut from the peanut oral immunotherapy being developed by Aimmune (AIMT).
09/12/19
LEER
09/12/19
NO CHANGE
LEER
Outperform
Aimmune Palforzia safety bodes well for DBV'S Viaskin Peanut, says SVB Leerink
SVB Leerink analyst Joseph Schwartz notes that FDA's Allergenic Products Advisory Committee released briefing documents pertaining to its upcoming AdCom panel discussion for Aimmune's (AIMT) Palforzia on Friday. Because efficacy has been robust for Palforzia, the analyst thinks investors will be acutely focused on safety, and believes the details surrounding Palforzia safety bode well for DBV Technologies' (DBVT) Viaskin Peanut as it could provide a convenient and safer alternative for peanut allergic patients. Despite slower onset of efficacy, Viaskin Peanut's favorable safety profile could promote longer-term use which previously has been shown to continue to improve on efficacy, he contends. Schwartz has an Outperform rating on DBV Technologies' shares.
AIMT Aimmune
$24.66

(0.00%)

09/11/19
STFL
09/11/19
NO CHANGE
STFL
Hold
Aimmune briefing docs look 'pretty benign,' says Stifel
After the FDA posted briefing documents ahead of its Allergenic Products Advisory Committee Meeting on September 13 to review Aimmune Therapeutics' peanut allergen powder, Palforzia, Stifel analyst Derek Archila said the documents "seem pretty benign" and did not generate any new issues. He expects the focus of the Adcom to be on safety, which is not "new" news, and thinks the document release should provide some relief for shares given that the "worst case" scenario in terms of the panel may be off the table. He sees the risk/reward as less favorable once Palforzia is approved given the commercial/logistical challenges he sees ahead, added Archila, who keeps a Hold rating on Aimmune shares.
09/11/19
PIPR
09/11/19
NO CHANGE
Target $60
PIPR
Overweight
Piper says FDA briefing docs remove key underpinning of Aimmune bear thesis
Piper Jaffray analyst Christopher Raymond said the FDA's briefing documents for its upcoming panel review of AR101, now called Palforzia, are "benign, even surprisingly positive," and he feels even more confident about the chances for approval of Aimmune's peanut allergy treatment. A key point in the documents is that the FDA is directing the panel to look at reactions to accidental exposures as perhaps a better predictor of real world utility than a double blinded placebo controlled food challenge, said Raymond, who contends that this "singular statement...removes a key underpinning from the bear thesis which points to the imbalance of systemic allergic reactions." The analyst, who anticipates a 2020 approval and revenue of over $1.5B by 2025, keeps an Overweight rating and $60 price target on Aimmune shares.
09/13/19
PIPR
09/13/19
NO CHANGE
PIPR
Aimmune's AR101 prospects derisked by FDA panel decision, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $60 price target on Aimmune after an FDA's Allergenic Products Advisory Committee, or APAC, voted in favor of the company's AR101 peanut allergy drug on both efficacy and safety. The analyst said, after the vote, he "increasingly likes the chances for Palforzia approval by late January 2020 (if not sooner)." Raymond noted that the stock is likely to open sharply higher on Monday as there is a 30% short interest in Aimmune, and said he is a buyer on the open as he sees "a lot of room to go."

TODAY'S FREE FLY STORIES

01:50
11/19/19
11/19
01:50
11/19/19
01:50
General news
Asian Market Update: »

Asian Market Update:…

EFC

Ellington Financial

$18.79

0.01 (0.05%)

20:29
11/18/19
11/18
20:29
11/18/19
20:29
Syndicate
Ellington Financial 4.2M share Spot Secondary priced at $18.20 »

The stock priced below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

HD

Home Depot

$238.98

1.64 (0.69%)

, MDT

Medtronic

$111.25

-0.86 (-0.77%)

20:25
11/18/19
11/18
20:25
11/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HD

Home Depot

$238.98

1.64 (0.69%)

MDT

Medtronic

$111.25

-0.86 (-0.77%)

TJX

TJX

$59.54

-0.25 (-0.42%)

TDG

TransDigm

$568.32

9.81 (1.76%)

ARMK

Aramark

$43.90

0.25 (0.57%)

KSS

Kohl's

$58.39

-0.71 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 05

    Dec

  • 11

    Dec

ACY

AeroCentury

$3.31

-0.66 (-16.62%)

20:01
11/18/19
11/18
20:01
11/18/19
20:01
Hot Stocks
AeroCentury sells one Bombardier CRJ900 to Aeronautical Support International »

AeroCentury announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$6.02

-0.14 (-2.27%)

19:29
11/18/19
11/18
19:29
11/18/19
19:29
Hot Stocks
Myovant Sciences up over 11% after announcing Phase 3 Study conference call »

Shares of Myovant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$29.95

-0.04 (-0.13%)

18:47
11/18/19
11/18
18:47
11/18/19
18:47
Hot Stocks
Invitation Homes CEO sells 70K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$369.50

-2.05 (-0.55%)

, LUV

Southwest

$57.77

-0.03 (-0.05%)

18:44
11/18/19
11/18
18:44
11/18/19
18:44
Periodicals
Boeing to provide Southwest board with 737 MAX update this week, Reuters says »

Boeing (BA) this week…

BA

Boeing

$369.50

-2.05 (-0.55%)

LUV

Southwest

$57.77

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

GBDC

Golub Capital

$17.79

0.045 (0.25%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Upgrade
Golub Capital rating change at Keefe Bruyette »

Golub Capital upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

GM

General Motors

$36.62

-0.25 (-0.68%)

, TM

Toyota

$143.53

-0.76 (-0.53%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Periodicals
CA to halt purchase of GM, Toyota, Fiat Chrysler vehicles, Reuters reports »

The state of California…

GM

General Motors

$36.62

-0.25 (-0.68%)

TM

Toyota

$143.53

-0.76 (-0.53%)

FCAU

Fiat Chrysler

$15.63

-0.39 (-2.43%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

, WUBA

58.com

$50.26

-1.35 (-2.62%)

18:38
11/18/19
11/18
18:38
11/18/19
18:38
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

WUBA

58.com

$50.26

-1.35 (-2.62%)

BILI

Bilibili

$16.39

-0.32 (-1.92%)

SAEX

SAExploration

$1.51

-0.05 (-3.21%)

CLVS

Clovis

$7.05

0.68 (10.68%)

NOW

ServiceNow

$266.56

6.65 (2.56%)

OKTA

Okta

$121.21

3.76 (3.20%)

SPLK

Splunk

$122.64

3.49 (2.93%)

WWD

Woodward

$113.64

-1.15 (-1.00%)

KRNT

Kornit Digital

$33.07

-1.13 (-3.30%)

ASH

Ashland

$78.65

0.03 (0.04%)

VNET

21Vianet

$8.28

0.23 (2.86%)

DHT

DHT Holdings

$7.52

-0.2 (-2.59%)

KRTX

Karuna Therapeutics

$94.70

77.44 (448.67%)

EGHT

8x8, Inc.

$20.78

0.13 (0.63%)

I

Intelsat

$7.98

-5.42 (-40.45%)

PFGC

Performance Food Group

$46.09

-0.08 (-0.17%)

EFC

Ellington Financial

$18.79

0.01 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 16

    Dec

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

LEVI

Levi Strauss

$17.06

-0.115 (-0.67%)

18:31
11/18/19
11/18
18:31
11/18/19
18:31
Hot Stocks
Levi Strauss CEO: I believe in the importance of innovation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$45.17

0.07 (0.16%)

18:17
11/18/19
11/18
18:17
11/18/19
18:17
Periodicals
Cisco sues former employees over claims of trade secret theft, Bloomberg says »

Cisco is suing two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

ABBV

AbbVie

$88.71

0.07 (0.08%)

18:09
11/18/19
11/18
18:09
11/18/19
18:09
Hot Stocks
AbbVie treatment of myelofibrosis granted FDA orphan status »

AbbVie's navitoclax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PRQR

ProQR Therapeutics

$6.27

-0.64 (-9.26%)

18:06
11/18/19
11/18
18:06
11/18/19
18:06
Hot Stocks
ProQR Therapeutics treatment of retinal dystrophy in P23H granted orphan status »

ProQR Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:04
11/18/19
11/18
18:04
11/18/19
18:04
Earnings
Bilibili sees Q4 revenue RMB1.93B-RMB1.98B »

Q4 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com sees Q4 revenue up 12%-15% in RMB terms »

Based on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Hot Stocks
Bilibili reports average MAUs reached 127.9M in Q3 »

Average monthly active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com reports Q3 adjusted EPS 96c, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:01
11/18/19
11/18
18:01
11/18/19
18:01
Earnings
Bilibili reports Q3 adjusted EPS (15c), consensus (14c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

DDOG

Datadog

$40.36

-0.33 (-0.81%)

, AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

17:56
11/18/19
11/18
17:56
11/18/19
17:56
Hot Stocks
Datadog announces support for AWS CloudFormation Registry and CLI »

Datadog (DDOG) announced…

DDOG

Datadog

$40.36

-0.33 (-0.81%)

AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

17:55
11/18/19
11/18
17:55
11/18/19
17:55
Conference/Events
Morgan Stanley analyst to hold an analyst/industry conference call »

Managing Director &…

GVA

Granite Construction

$26.50

-0.6 (-2.21%)

17:54
11/18/19
11/18
17:54
11/18/19
17:54
Hot Stocks
Granite Construction awarded $14M airfield improvement project in California »

Granite announced it was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$44.46

-1.37 (-2.99%)

, MSFT

Microsoft

$150.35

0.4 (0.27%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Initiation
Zscaler, Microsoft initiated at DA Davidson »

Zscaler initiated with a…

ZS

Zscaler

$44.46

-1.37 (-2.99%)

MSFT

Microsoft

$150.35

0.4 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 16

    Dec

OKTA

Okta

$121.21

3.76 (3.20%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Upgrade
Okta rating change at DA Davidson »

Okta pullback represents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

PANW

Palo Alto Networks

$248.50

1.465 (0.59%)

17:48
11/18/19
11/18
17:48
11/18/19
17:48
Initiation
Palo Alto Networks initiated at DA Davidson »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.